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Objectives We hypothesized that women with lower extremity peripheral arterial disease (PAD) would have greater mobility
loss and faster functional decline than men with PAD.
Background Whether rates of mobility loss or functional decline differ between men and women with PAD is currently
unknown.
Methods Three hundred eighty men and women with PAD completed the 6-min walk, were assessed for mobility disabil-
ity, and underwent measures of 4-m walking velocity at baseline and annually for up to 4 years. Computed
tomography-assessed calf muscle characteristics were measured biannually. Outcomes included becoming un-
able to walk for 6 min continuously among participants who walked continuously for 6 min at baseline. Mobility
loss was defined as becoming unable to walk for a quarter mile or to walk up and down 1 flight of stairs without
assistance among those without baseline mobility disability. Results were adjusted for age, race, body mass in-
dex, physical activity, the ankle brachial index, comorbidities, and other confounders.
Results At 4 years of follow-up, women were more likely to become unable to walk for 6 min continuously (hazard ratio:
2.30, 95% confidence interval: 1.30 to 4.06, p  0.004), more likely to develop mobility disability (hazard ratio:
1.79, 95% confidence interval: 1.30 to 3.03, p  0.030), and had faster declines in walking velocity (p  0.022)
and the distance achieved in the 6-min walk (p  0.041) compared with men. Sex differences in functional de-
cline were attenuated after additional adjustment for baseline sex differences in calf muscle area.
Conclusions Women with PAD have faster functional decline and greater mobility loss than men with PAD. These sex differ-
ences may be attributable to smaller baseline calf muscle area among women with PAD. (J Am Coll Cardiol
2011;57:707–14) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.042Lower extremity peripheral arterial disease (PAD) affects 8
million men and women in the U.S. (1). Among older
individuals, the prevalence of PAD is similar to or even
slightly higher in women as compared with men (1–3). A
previous cross-sectional study demonstrated that women
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accepted September 10, 2010.with PAD have greater functional impairment and poorer
lower extremity strength than men with PAD (4). However,
little is known about sex differences in rates of functional
decline or changes in calf muscle characteristics over time
between men and women with PAD.
In this observational, longitudinal study, we compared rates
of mobility loss, decline in 6-min walk performance, and
decline in walking velocity between men and women with
PAD at 4 years of follow-up. We also compared baseline
measures of calf muscle characteristics and leg strength and
changes in these muscle outcomes between men and women
with PAD at 4 years of follow-up. We hypothesized that
women with PAD would have greater mobility loss, faster
functional decline, and more adverse changes in calf muscle
characteristics over time compared with men with PAD. We
further hypothesized that greater mobility loss and faster
functional decline among women with PAD as compared with
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more adverse muscle characteris-
tics among women with PAD as
compared with men with PAD.
Methods
Study overview. The Institu-
tional Review Boards of North-
western University and Catholic
Health Partners Hospital ap-
proved the protocol. Participants gave written informed con-
sent. Participants were in the WALCS (Walking and Leg
Circulation Study) II cohort, a prospective, observational study
designed to identify mechanisms of functional decline in PAD
(5,6). Participants underwent baseline measures and returned
annually for follow-up for up to 4 follow-up visits. Data
collection took place between November 6, 2002, and October
16, 2009. Every effort was made to maximize follow-up by
scheduling follow-up visits before or after their due date, if a
participant was otherwise unable to return for follow-up
testing.
Participant identification. PAD participants were 59 years
of age and older and were identified from among consecu-
tive patients diagnosed with PAD in Chicago-area nonin-
vasive vascular laboratories (5,6). A small number of PAD
participants were identified from among consecutive pa-
tients in a large general internal medicine practice at
Northwestern with a low ankle brachial index (ABI) at their
study visit. PAD was defined as ABI 0.90 (2,5,6). Ab-
sence of PAD was defined as ABI 0.90 or more and 1.30 or
less (5,6).
Participation rates and exclusion criteria for the WALCS II
cohort have been described and are summarized briefly here
(6). Patients with dementia were excluded because of their
inability to answer questions accurately. Nursing home
residents, wheelchair-bound patients, and patients with foot
or leg amputations were excluded because they had severely
impaired functioning at baseline. Non–English-speaking
patients were excluded because investigators were not fluent
in non-English languages. Patients with recent major sur-
gery were excluded.
ABI measurement. A hand-held Doppler probe (Nicolet
Vascular Pocket Dop II, Nicolet Biomedical, Inc., Golden,
Colorado) was used to obtain systolic pressures in the right
and left brachial, dorsalis pedis, and posterior tibial arteries
(5–7). Each pressure was measured twice. The ABI was
calculated by dividing the mean of the dorsalis pedis and
posterior tibial pressures in each leg by the mean of the 4
brachial pressures (7). Zero values for the dorsalis pedis and
posterior tibial pulses were set to missing for the ABI
calculation. Average brachial pressures in the arm with
highest pressure were used when 1 brachial pressure was
higher than the opposite brachial pressure in both measure-
ment sets and the 2 brachial pressures differed by 10 mm Hg
Abbreviations
and Acronyms
ABI  ankle brachial index
BMI  body mass index
CT  computed
tomography
PAD  peripheral arterial
diseaseor more in at least 1 measurement set, because in such cases,subclavian stenosis is possible (8). The lowest leg ABI was
used in analyses.
Functional outcomes. Functional outcomes were assessed
annually and consisted of mobility loss, becoming unable to
walk for 6 min continuously without stopping, decline in
6-min walk performance of 20% or more, and average
annual declines in 6-min walk performance, usual paced
4-m walking velocity, and fastest paced 4-m walking veloc-
ity (5,9).
6-min walk. Following a standardized protocol (9), partic-
ipants walk up and down a 100-foot hallway for 6 min after
instructions to cover as much distance as possible. The test
administrator recorded whether the participant stopped
during the 6-min walk. Participants who stopped at baseline
were excluded from analyses of becoming unable to com-
plete the 6-min walk without stopping.
4-m walking velocity. Walking velocity was measured
with a 4-m walk performed at usual and fastest pace, based
on a previous study (9,10). Each walk was performed twice.
The faster walk in each pair was used in analyses (9,10).
Mobility measures. At baseline and at each follow-up visit,
participants were asked to indicate whether they could walk
a quarter mile and whether they could climb up and down
1 flight of stairs: 1) on their own; 2) with assistance; or 3)
not at all (5,10). Mobility loss was defined as becoming
unable to walk up and down one flight of stairs or to walk
a quarter mile without assistance among those without
mobility limitations at baseline (5,10). Those unable to
return for follow-up were interviewed by telephone for the
mobility outcome measure.
Calf muscle characteristics. Calf muscle measurements
were assessed with computed tomography (CT) at baseline
and at the 2- and 4-year follow-up visits using a CT scanner
(LightSpeed, General Electric Medical Systems, Waukesha,
Wisconsin) (5,6). Cross-sectional images of the calves
measuring 2.5 mm were obtained at 66.7% of the distance
from the distal to the proximal tibia (6,7). Cross-sectional
images were analyzed using BonAlyse (BonAlyse Oy, Jyvas-
kyla, Finland), a software for processing CT images that
identifies muscle tissue, fat, and bone (11). The muscle
outline was traced manually, excluding subcutaneous fat and
bone. When quantifying muscle area, the BonAlyse soft-
ware quantifies voxels within a range corresponding to
muscle density (9 to 271 mg/cm3) and excludes voxels
orresponding to fat density (270 to 8 mg/cm3). Intra-
uscular fat is quantified by summing voxels corresponding
o fat within muscle tissue. Cadaver studies demonstrate
hat these methods provide an estimate of muscle cross-
ectional area that is highly correlated with direct anatomic
easures (12). Because larger individuals require greater
uscle mass to support their frame, muscle area was
djusted for the square of individual tibia length (5). Muscle
ensity measures the quantity of muscle per volume within
he voxel range corresponding to muscle (9 to 271 mg/cm3)and is a measure of muscle quality.
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measured at baseline and annually during follow-up using a
computer-linked strength chair with a transducer placed for
knee extension (Good Strength Chair, Metitur Oy, Jyvask-
lya, Finland) (13). Data were collected electronically by
computer over 6 s. Strength measurements using the Good
Strength Chair have high test–retest reliability (Pearson prod-
uct moment correlations: 0.88 to 0.96) (14). Two trials were
performed. Maximum strength was used in analyses (13).
Comorbidities. Comorbidities assessed at baseline were
diabetes, angina, myocardial infarction, heart failure, cancer,
chronic lung disease, lower extremity arthritis, spinal steno-
sis, spinal disk disease, and stroke (15). Disease-specific
algorithms that combine data from the patient report,
medical record review, medications, laboratory values, and a
questionnaire completed by the participant’s primary care
physician were used to verify and document baseline comor-
bidities other than knee and hip arthritis, based on criteria
previously developed (15). American College of Rheuma-
tology criteria were used to document presence of knee and
hip osteoarthritis (16,17).
Other measures. Height and weight were measured at
baseline. Body mass index (BMI) was calculated as weight
in kilograms per height in square meters. Cigarette smoking
history was determined with the patient report. At baseline,
participants were asked to report the number of blocks they
walked during the previous week. At each follow-up visit,
we used the patient report, a primary care physician ques-
tionnaire, and medical record review to identify lower
extremity revascularizations since the prior visit.
Statistical analyses. Analyses of covariance was used to
compare baseline clinical characteristics between men and
women with PAD, adjusting for age. A priori, a p value
0.05 was considered statistically significant. For the out-
comes of loss of the ability to walk continuously for 6 min
without stopping, mobility loss, and a 20% or more decline
in distance achieved in the 6-min walk test, Cox regression
analyses were used to compare rates of each functional
outcome between men and women with PAD, adjusting for
confounders. We used PROC PHREG to perform these
analyses and TIES equal to DISCRETE for the discrete
time point in years. For the outcome of mobility loss,
participants with mobility limitations at baseline were ex-
cluded. For the outcome of becoming unable to walk for 6
min continuously, participants unable to walk for 6 min
without stopping at baseline were excluded. Person-time
was calculated as the number of months from the baseline
visit to the date of the most recent visit (last seen) or the
date of the visit during which each functional outcome of
interest was first reported, whichever came first. Participants
who died before experiencing an outcome measure or who
underwent lower extremity revascularization during follow-up
were censored at the date of their last visit before these events.
In these analyses, model I adjusted for age, race, ABI, BMI,
smoking, comorbidities (diabetes, angina, myocardial infarc-
tion, heart failure, cancer, chronic lung disease, knee arthritis,hip arthritis, spinal stenosis, disk disease, and stroke), and
physical activity. To determine whether sex differences in
baseline calf muscle characteristics or knee extension
strength may explain sex differences in functional decline,
model I was repeated with additional adjustment for base-
line measures of each calf characteristic, knee extension
strength, and baseline 6-min walk performance, respectively.
We tested the proportional hazards assumption for the 3
outcome measures using martingale residuals-based methods
(18). There were no significant deviations from the propor-
tional hazards assumption.
Changes in continuous outcome measures, including
functional performance (6-min walk distance and 4-m
walking velocity), knee extension strength, and calf muscle
characteristics were compared between men and women
with PAD using a longitudinal or repeated-measures anal-
ysis of covariance and a mixed model approach. PROC
MIXED in SAS software (SAS Institute, Inc., Cary, North
Carolina) was applied for this procedure. The within-
subject correlations were modeled with a subject-specific
random effect. The primary dependent variables for each
analysis were the successive annual differences in each
outcome of interest (i.e., the difference in 6-min walk
distance between baseline and the first follow-up visit,
between the first and second follow-up visit, between the
second and third follow-up visit, and so on). Sex differences
in decline for each continuous outcome were compared
using an analysis of covariance, adjusting for baseline age,
race, BMI, smoking, physical activity, comorbidities, and
the corresponding prior year performance or muscle char-
acteristic (model I). Analyses of average annual decline in
6-min walk performance or 4-m walking velocity were
repeated with additional adjustment for each baseline calf
muscle characteristic and baseline knee extension strength,
respectively, to determine whether sex differences in functional
decline could be explained by sex differences in baseline muscle
characteristics. Analyses were performed using SAS statistical
software (version 9.2, SAS Institute, Inc.).
Results
Four-hundred fifty-five participants in the WALCS II
cohort had a baseline ABI of less than 0.90 and completed
baseline calf muscle measures or underwent measurement of
baseline knee extension strength. Of these, 70 (15%) did not
meet inclusion criteria for any functional outcomes and 5
(1%) did not have data for at least 1 covariate measure. Of
the 75 who did not meet inclusion criteria, 32 (42.7%) were
women. Mean follow-up was 47 months (range 8 to 81
months).
The mean age  SD of the women was 76.0  8.1 years,
and that of men was 74.2  7.7 years (p  0.024). Table 1
shows baseline characteristics of men and women with
PAD, adjusting for age. Women with PAD included higher
prevalences of African Americans, those with knee arthritis,
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compared with men with PAD (Table 1). Adjusting for age,
women walked fewer blocks per week and had poorer 6-min
walk performance, smaller calf muscle area, lower calf
Age-Adjusted Baseline Characteristics of Men VWith Peripheral Arterial Diseas (n  380)Table 1 Age-Adjusted B seline Charact ristWith Peripheral Arterial Disease (n
Baseline Characteristics
African American (%)
Ankle brachial index
Body mass index (kg/m2)
Current cigarette smoker (%)
Cancer (%)
Diabetes mellitus (%)
Pulmonary disease (%)
Angina pectoris (%)
Myocardial infarction (%)
Stroke (%)
Heart failure (%)
Hip arthritis (%)
Knee arthritis (%)
Disc disease (%)
Spinal stenosis (%)
No. of blocks walked during the past week
6-min walk at baseline (ft) 1
Usual speed 4-m walking velocity (m/s)
Fastest speed 4-m walking velocity (m/s)
Muscle area (mm2) 4
Muscle percent fat (%)
Muscle density (g/cm2)
Knee extension strength (Newtons)
The values in parentheses represent standard errors.
Adjusted Associations of Sex With Decline in Functional Performanin Low r Extremity Muscle Among P riph ral Arterial Disease PartTable 2 Adjusted Associations of Sex With Decline in Functioin Lower Extremity Muscle Among Peripheral Arterial D
Women (n
Outcome n
H
(95% Co
p value categorical outcomes for functional
performance
Becoming unable to walk for 6 min
continuously during follow-up
108 2.30
Mobility loss 142 1.79
20% decline in 6-min walk performance
during follow-up
168 1.49
Average annual decline in functional performance
6-min walk performance (ft/yr) 159 –57.27
Usual paced 4-m walking velocity (m/s/yr) 167 –0.036
Fast-paced 4-m walking velocity (m/s/yr) 164 –0.043
Average annual change in muscle outcomes
Calf muscle area (mm2/yr) 134 –220.1
Calf muscle percent fat (%/yr) 134 0.80
Calf muscle density (g/cm3/yr) 134 –0.74
Knee extension isometric strength (Newtons/yr) 164 –2.89Analyses adjust for age, race, body mass index, comorbidities, physical activity, smoking, and ankle b
characteristics additionally adjusted for prior year performance or the relevant calf muscle characteristicmuscle density, and poorer knee extension strength com-
pared with men (Table 1).
Table 2 compares rates of functional decline and changes
in muscle characteristics between men and women with
Womenf Men Versus Women
0)
ale
80)
Male
(n  200) p Value
7 8.8 0.001
(0.01) 0.64 (0.01) 0.152
(0.4) 28.3 (0.4) 0.392
3 13.0 0.522
6 15.6 0.136
2 33.4 0.385
4 38.1 0.155
6 40.6 0.005
7 28.6 0.284
2 20.1 0.980
9 32.5 0.067
9 3.0 0.352
.8 9.6 0.040
.9 35.3 0.023
.2 12.1 0.099
(4.1) 39.2 (3.9) 0.001
(27.9) 1,222.9 (26.3) 0.001
(0.01) 0.91 (0.01) 0.001
(0.02) 1.24 (0.02) 0.001
(86.8) 6113.0 (82.8) 0.001
(1.0) 10.9 (1.0) 0.279
(0.3) 32.9 (0.3) 0.042
(7.7) 321.0 (6.8) 0.001
nd Changests (n  380)rform c and Changes
se Participants (n  380)
) Men (n  200)
Ratio
ce Interval) n
Hazard Ratio or Average
Annual Change
(95% Confidence Interval) p Value
o 4.06) 139 1.00 0.004
o 3.03) 186 1.00 0.030
o 2.26) 185 1.00 0.058
2 to –42.02) 181 –34.25 (48.23 to –20.27) 0.041
4 to –0.028) 186 –0.022 (–0.030 to –0.015) 0.022
3 to –0.033) 185 –0.031 (–0.041 to –0.022) 0.120
8 to –147.5) 166 –358.5 (–421.7 to –295.4) 0.015
o 1.28) 166 1.80 (1.38 to 2.22) 0.003
to –0.49) 166 –0.75 (–0.97 to –0.53) 0.949
to –0.92) 186 –10.2 (–13.2 to –7.1) 0.003ersusics o
 38
Fem
(n  1
24.
0.62
27.9
15.
21.
29.
45.
26.
23.
20.
23.
4.
16
46
18
18.4
,014.0
0.81
1.07
676.1
12.4
32.1
211.7ce ai ipal Pe
isea
 180
azard
nfiden
(1.30 t
(1.06 t
(0.99 t
(–75.5
(–0.04
(–0.05
(–292.
(0.33 t
(–0.99
(–6.37rachial index. Analyses of changes in 6-min walk distance, 4-m walking velocity, and muscle
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become unable to walk for 6 min continuously, had greater
mobility loss, and had greater average annual declines in
6-min walk distance and usual-paced 4-m walking velocity,
adjusting for age, race, BMI, comorbidities, physical activ-
ity, smoking, prior year performance (6-min walk and
walking velocity outcomes only), and ABI (Table 2).
Compared with men, women had less annual decline in
calf muscle area, less increase in calf muscle percent fat, and
less decline in knee extension isometric strength adjusting
for age, race, BMI, comorbidities, physical activity, smok-
ing, prior year calf muscle or strength measurement, and
ABI (Table 2).
To determine whether baseline sex differences in func-
tional performance might have influenced our findings
regarding mobility loss, becoming unable to walk for 6 min
continuously, and 20% or more decline in 6-min walk
performance, we repeated analyses for these outcomes after
additionally adjusting for baseline 6-min walk performance.
After additional adjustment for baseline 6-min walk perfor-
mance, associations of female sex with faster decline were
attenuated. Hazard ratios for mobility loss, becoming
unable to walk for 6 min continuously, and 20% or more
decline in 6-min walk distance were 1.35 (95% confi-
dence interval: 0.77 to 2.36, p  0.288), 1.70 (95%
confidence interval: 0.94 to 3.09, p  0.088), and 1.27
(95% confidence interval: 0.82 to 1.97, p  0.289), respec-
Adjusted Associations of Sex With Functional Decline in Peripheral ArWith and Without Adjustment for Baseline Calf Muscl C a cteTable 3 Adjusted As ociations of Sex With Functional Decline inWith and Without Adjustment for Baseline Calf Musc
Women (n  1
Model n
Hazard R
Avera
(95% Confi
Becoming unable to walk for 6 min
continuously during follow-up
Base model 107 2.32 (1.
Base model  baseline calf muscle area 107 1.83 (0.
Mobility loss
Base model 138 1.88 (1.
Base model  baseline calf muscle area 138 1.06 (0.
20% decline in 6-min walk during follow-up
Base model 164 1.41 (0.
Base model  baseline calf muscle area 164 1.39 (0.
Average annual decline in 6-min walk
distance (feet)
Base model 154 –54.59 (–6
Base model  baseline calf muscle area 154 –50.39 (–6
Average annual decline in usual paced 4-m
walking velocity (m/s)
Base model 162 –0.036 (–0
Base model  baseline calf muscle area 162 –0.032 (–0
Average annual decline in fast-paced 4-m
walking velocity (m/s)
Base model 159 –0.041 (–0
Base model  baseline calf muscle area 159 –0.038 (–0The base model adjusts for age, race, body mass index, comorbidities, physical activity, smoking, and ankl
adjust for prior year performance. The base model  baseline calf muscle adjusts for variables in the batively. These findings suggest that baseline sex differences in
functional performance may contribute to higher rates of
decline in these 3 outcomes among women as compared
with men with PAD.
Associations of sex with functional decline, with and
without adjustment for baseline calf muscle area, are shown
in Table 3. Data in Table 3 are limited to participants with
aseline calf muscle area data. In this subset of 369
articipants, women had a higher rate of becoming unable
o walk for 6 min continuously during follow-up, a higher
ate of mobility loss, and greater decline in the usual-paced
-m walking velocity, adjusting for age, race, BMI, comor-
idities, physical activity, smoking, prior year performance
for analyses of average annual declines only), and ABI
Table 3, base model). These associations of female sex with
aster functional decline were attenuated and no longer
tatistically significant after additional adjustment for base-
ine calf muscle area (Table 3). Similarly, the association of
emale sex with greater decline in usual-paced walking
elocity was no longer statistically significant after the base
odel was adjusted additionally for calf muscle density
0.035 m/s/year for women vs. 0.024 m/s/year for men,
 0.052). However, remaining significant associations of
female sex with functional decline were not attenuated and
remained statistically significant after additional adjustment
of the base model for calf muscle density. Similarly, the
significant associations of female sex with faster functional
Diseases (n  369)heral Arterial Disease
haracteristics (n  369)
Men (n  193)
r Annual
ange
Interval) n
Hazard Ratio or Annual
Average Change
(95% Confidence Interval) p Value
.11) 135 1.00 0.004
.49) 135 1.00 0.065
.20) 180 1.00 0.023
.97) 180 1.00 0.846
.15) 179 1.00 0.112
.26) 179 1.00 0.179
o –9.30) 172 –34.18 (–48.26 to –20.09) 0.070
o –33.66) 172 –37.85 (–53.12 to –22.58) 0.332
o –0.027) 177 –0.023 (–0.031 to –0.015) 0.038
o –0.023) 177 –0.027 (–0.035 to –0.019) 0.496
o –0.031) 172 –0.032 (–0.041 to –0.022) 0.224
o –0.027) 172 –0.035 (–0.045 to –0.025) 0.771terialristicPerip
le C
76)
atio o
ge Ch
dence
31 to 4
96 to 3
10 to 3
57 to 1
92 to 2
86 to 2
9.88 t
7.11 t
.044 t
.041 t
.051 t
.048 te brachial index. Analyses of declines in 6-min walk distance and 4-m walking velocity additionally
se model and adds calf muscle area.
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nificant after additional adjustment of the base model for
calf muscle percent fat (data not shown). Together, these
findings suggest that lower baseline calf muscle area among
women may mediate the association of female sex with
faster functional decline among participants with PAD. In
contrast, these findings suggest that baseline sex differences
in calf muscle percent fat do not mediate associations of
female sex with faster functional decline.
Associations of sex with functional decline, with and
without adjustment for baseline knee extension isometric
strength, are shown in Table 4. Analyses are limited to
participants with baseline knee extension strength data (n
285). In this subset, women had a higher incidence of
becoming unable to walk for 6 min continuously during
follow-up and faster declines in 4-m walking velocity at
usual and fastest pace, adjusting for age, race, BMI, comor-
bidities, physical activity, smoking, prior year performance
(6-min walk and walking velocity outcomes only), and ABI
(Table 4, base model). Most of these associations were
attenuated after additional adjustment for baseline knee
extension strength (Table 4). The association of female sex
with faster decline in walking velocity remained statistically
significant even after adjustment for baseline knee extension
strength (Table 4). These findings suggest that baseline
higher knee extension strength in men as compared with
women may mediate the association of female sex with
faster functional decline compared with men.
Adjusted Associations of Sex With Functional Decline Among PartiWith an Without Adjustment for Baseline Knee Extension Isome rTable 4 Adj ste Associati ns of Sex With Functional DeclineWith and Without Adjustment for Baseline Knee Exten
Women (
Model n (95% C
Becoming unable to walk for 6 min continuously
during follow-up
Base model 78 2.4
Base model  knee extension strength 78 1.9
Mobility loss
Base model 105 1.8
Base model  knee extension strength 105 1.2
Decline in 6-min walk by 20% during follow-up
Base model 116 1.3
Base model  knee extension strength 116 1.0
Average annual decline in 6-min walk distance (ft)
Base model 111 –48.6
Base model  knee extension strength 111 –40.8
Average annual decline in usual paced 4-m walking
velocity (m/s)
Base model 114 –0.04
Base model  knee extension strength 114 –0.03
Average annual decline in fastest paced 4-m walking
velocity (m/s)
Base model 113 –0.04
Base model  knee extension strength 113 –0.04The base model adjusts for age, race, body mass index, comorbidities, physical activity, smoking, and ankl
adjust for prior year performance. The base model  knee extension strength adjusts for baseline kneeDiscussion
Our data shows that at 47 months of follow-up, women
with PAD were more likely to become unable to walk for 6
min continuously, had a higher incidence of mobility loss,
and had faster declines in 6-min walk distance and usual-
paced walking velocity compared with men with PAD.
These findings were independent of potential confounders
including sex differences in comorbid disease prevalence and
physical activity. However, after adjustment for baseline sex
differences in functional performance, the associations of
female sex with becoming unable to walk for 6 min
continuously and mobility loss were attenuated and no
longer statistically significant. These latter findings suggest
that the poorer functional performance at baseline among
women compared with men resulted in women being closer
at baseline to the thresholds for the outcomes of mobility
loss and becoming unable to walk for 6 min continuously as
compared with men.
At baseline, women had smaller calf muscle area, lower
calf muscle density, and poorer knee extension strength as
compared with men. When sex differences in functional
decline were adjusted for baseline sex differences in calf
muscle area and knee extension strength, associations of
female sex with faster functional decline were attenuated
and no longer statistically significant. These findings sug-
gest that lower calf muscle area and reduced knee extension
strength in women at baseline may explain in part the faster
ts With Peripheral Arterial Diseaserength (n  285)g Participants With P pheral Arterial Disease
Isometric Strength (n  285)
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with men with PAD.
Although men had more favorable calf muscle character-
istics and greater knee extension strength at baseline, calf
muscle area and knee extension strength declined more
rapidly in men than in women over time, whereas calf
muscle percent fat increased more rapidly in men. Thus,
men with PAD experienced more rapid deterioration in
lower extremity muscle characteristics and strength than
women. Our findings suggest that men with PAD have
greater lower extremity muscle reserve than women, but are
more susceptible to loss of favorable muscle characteristics
and function compared with women. The greater baseline
muscle reserve among men with PAD may protect them
against functional decline, relative to women with PAD.
Mechanisms for the faster rates of decline in knee
extension strength and more rapid progression of adverse
changes in calf muscle characteristics among men as com-
pared with women with PAD could not be discerned from
the current study. However, a previous longitudinal study of
participants without PAD demonstrated that loss of muscle
mass was approximately twice as rapid in men as compared
with women (19). Declining levels of testosterone in older
men may contribute to declines in skeletal muscle charac-
teristics and performance in men over time (19–21).
Although PAD is common among both men and women
in older populations (1–3), little is known about sex differ-
ences in functional decline among patients with PAD.
Identifying sex differences in lower extremity outcomes
among patients with PAD will help clinicians to provide
prognostic information and to make optimal therapeutic
decisions for patients with PAD. Our findings demonstrate
that sex differences in functional decline were greatest for
the outcomes of mobility loss and becoming unable to walk
for 6 min continuously than for the continuous outcome
measures of distance achieved in the 6-min walk and 4-m
walking velocity. Our results suggest that because of their
poorer baseline performance, women were closer at baseline
to the outcomes of mobility loss and becoming unable to
walk for 6 min continuously compared with men with PAD.
Among PAD participants in our original WALCS co-
hort, we previously reported no sex differences in declines in
6-min walk distance or walking velocity at 3 years of
follow-up (22). At 4 years of follow-up, women had a
greater decline in walking velocity compared with men,
although the findings did not achieve statistical significance
(p  0.052). As compared with this prior study, the current
study consists of the WALCS II cohort, assessed all
outcomes through a mean follow-up of 47 months, and
assessed changes in CT-measured muscle characteristics,
muscle strength, and additional functional outcomes com-
pared with the previous study (22).
Study limitations. First, data are observational. Observed
associations should not be construed as causal. Second,
participants were recruited from Chicago-area academic
medical centers. Findings may not be generalizable to PADpatients outside of academic medical centers. Third, residual
confounding from the older age of women with PAD as
compared with men with PAD may have influenced our
finding that women with PAD have faster rates of func-
tional decline than men with PAD. However, despite this
potential for residual confounding, our results still demon-
strated that men had more rapid adverse changes in calf
muscle characteristics and muscle strength over time.
Fourth, our analyses included multiple sex comparisons. A
priori, we selected p  0.05 as the level of statistical
ignificance. Although not all comparisons were statistically
ignificant, our findings consistently demonstrated that
unctional decline was greater in women than in men.
imilarly, adverse changes in muscle characteristics consis-
ently occurred more rapidly in men than in women.
onclusions
omen with PAD have faster rates of functional decline
han men with PAD. These differences seem to be related in
art to more favorable calf muscle characteristics and lower
xtremity strength at baseline in men as compared with
omen with PAD. A previous study demonstrated that
ower extremity strength training improves treadmill walk-
ng performance and quality of life in participants with
AD (23). Further study is needed to determine whether
nterventions to increase calf muscle area, to improve lower
xtremity strength among women with PAD, or both can
low their faster functional decline as compared with men
ith PAD.
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